Lataa...
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
OBJECTIVE: We undertook this phase III study to evaluate baricitinib, an orally administered JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis (RA) who had received no or minimal conventional synthetic d...
Tallennettuna:
| Julkaisussa: | Arthritis Rheumatol |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5347954/ https://ncbi.nlm.nih.gov/pubmed/27723271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.39953 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|